Ozempic and pregnancy: what the actual data says

What did @timsayedmd actually say?

Dr. Tim Syed, a board-certified plastic surgeon running a weight loss program, made a fairly simple argument: if you're diabetic and using GLP-1 drugs for blood sugar control, talk to your doctor about staying on them during pregnancy. If you're using them purely for weight loss, stop. He summed it up as "you don't want to be losing weight during pregnancy" and framed the diabetic use case as a nuanced physician conversation rather than a blanket yes or no. He did not directly answer the birth defect question with data, which is notable given that's what the video title promises.

That's the core of it. No dosing advice, no dramatic claims about safety or harm. The guidance is conservative and clinician-deferred, which is generally appropriate for a social media format. But the devil is in what he left out.

Does the science back this up?

Mostly, yes, but the evidence base here is genuinely thin, and viewers deserve to know that. The FDA classifies semaglutide as Pregnancy Category X equivalent under current labeling, meaning it is not recommended during pregnancy based on animal studies showing fetal harm at clinically relevant doses.

Human data is sparse and largely observational. A 2024 study by Winther et al. published in the New England Journal of Medicine examined Danish registry data and found no statistically significant increase in major birth defects among infants exposed to GLP-1 receptor agonists in the first trimester compared to unexposed controls. However, the sample sizes were modest and the authors themselves called for larger studies before drawing firm conclusions. Novo Nordisk's own prescribing information for Ozempic explicitly states: discontinue when pregnancy is recognized. The American College of Obstetricians and Gynecologists has not issued a blanket endorsement of GLP-1 use in pregnancy for any indication. For diabetic patients, insulin remains the standard of care during pregnancy, not GLP-1 agonists.

What did they get wrong (or right)?

He got the general framework right. Weight loss during pregnancy is genuinely contraindicated, and telling patients on GLP-1s for obesity to stop is consistent with current clinical guidance. That part deserves credit.

What he glossed over, though, is significant. The suggestion that diabetic patients might safely "continue on the medications" oversimplifies a situation where current obstetric guidelines actually favor switching to insulin during pregnancy, not continuing GLP-1 agonists. The American Diabetes Association's 2024 Standards of Care state that insulin is the preferred pharmacologic agent for managing type 2 diabetes in pregnancy because of its established safety record and inability to cross the placenta. GLP-1 receptor agonists can cross the placental barrier, and their effects on fetal pancreatic development are not fully characterized in humans.

He also completely sidestepped the actual birth defect question his video title raises. The Winther et al. 2024 data is reassuring but preliminary. Framing diabetic GLP-1 use as potentially safe without acknowledging that insulin is the standard of care is a real gap. It's not wrong enough to call dangerous, but it's incomplete in a way that 65,000 viewers might not catch.

What should you actually know?

The honest answer to the birth defect question is: we don't know enough yet. Animal studies raised flags. Human observational data so far is cautiously reassuring but underpowered. That uncertainty matters.

If you get pregnant while on semaglutide or any GLP-1 drug, the standard clinical recommendation is to stop the medication. This applies regardless of whether you're using it for diabetes or weight loss. For diabetic patients who need pharmacologic management during pregnancy, insulin is the established first-line option, not a continued GLP-1 prescription. Novo Nordisk maintains a pregnancy exposure registry (1-800-727-6500) specifically because the human data is still being collected.

One additional practical point worth knowing: GLP-1 drugs can reduce nutrient absorption and cause nausea-driven food restriction. During pregnancy, adequate caloric and micronutrient intake is non-negotiable for fetal development. Even if the drug itself were proven safe, its appetite-suppressing mechanism creates downstream nutritional risks that make use during pregnancy complicated.

• Stop GLP-1 drugs when pregnancy is confirmed, per current FDA labeling and prescribing guidelines.
• For type 2 diabetes in pregnancy, discuss insulin as the preferred option with your OB and endocrinologist.
• First-trimester exposure data from Winther et al. (2024, NEJM) is cautiously reassuring but not definitive.
• The birth defect risk in humans remains genuinely uncertain, not proven safe.